140 related articles for article (PubMed ID: 37776978)
21. The effect of a next generation factor VIII mimetic bispecific antibody (Mim8) on assays of factor VIII activity and thrombin generation.
Bowyer AE; Kitchen S; Ezban M
J Thromb Haemost; 2023 Mar; 21(3):480-487. PubMed ID: 36696203
[TBL] [Abstract][Full Text] [Related]
22. Safety of FEIBA and emicizumab (SAFE): Dose escalation study evaluating the safety of in vivo administration of activated prothrombin complex concentrate in haemophilia A patients on emicizumab.
Kizilocak H; Marquez-Casas E; Malvar J; Young G
Haemophilia; 2023 Jan; 29(1):100-105. PubMed ID: 36287631
[TBL] [Abstract][Full Text] [Related]
23. Measurement of recombinant porcine factor VIII in patients with congenital haemophilia A and inhibitors in the presence of emicizumab.
Pfrepper C; Klamroth R; Ettingshausen CE; Petros S; Siegemund A; Siegemund T
Haemophilia; 2024 Mar; 30(2):545-553. PubMed ID: 38343119
[TBL] [Abstract][Full Text] [Related]
24. Elevated factor VIII enhances thrombin generation in the presence of factor VIII-deficiency, factor XI-deficiency or fondaparinux.
Szlam F; Sreeram G; Solomon C; Levy JH; Molinaro RJ; Tanaka KA
Thromb Res; 2011 Feb; 127(2):135-40. PubMed ID: 21144556
[TBL] [Abstract][Full Text] [Related]
25. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II.
van 't Veer C; Mann KG
J Biol Chem; 1997 Feb; 272(7):4367-77. PubMed ID: 9020158
[TBL] [Abstract][Full Text] [Related]
26. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
Lenting PJ; Denis CV; Christophe OD
Blood; 2017 Dec; 130(23):2463-2468. PubMed ID: 29042366
[TBL] [Abstract][Full Text] [Related]
27. Multicenter evaluation of the hemostatic activity of emicizumab in patients with severe hemophilia A.
Josset L; Leuci A; Janbain M; De-Wreede A; Desage S; Lienhart A; Bin V; Lebert D; Delavenne X; Dargaud Y
J Thromb Haemost; 2024 Jul; 22(7):1857-1866. PubMed ID: 38583717
[TBL] [Abstract][Full Text] [Related]
28. Haemostatic effect of adding tranexamic acid to emicizumab prophylaxis in severe haemophilia A: A preclinical study.
Janbain M; Enjolras N; Bolbos R; Brevet M; Bordet JC; Dargaud Y
Haemophilia; 2021 Nov; 27(6):1002-1006. PubMed ID: 34644431
[TBL] [Abstract][Full Text] [Related]
29. The in vitro effect of anticoagulant agents on coagulation and fibrinolysis in the presence of emicizumab in the plasmas from patients with haemophilia A.
Onishi T; Harada S; Shimo H; Tashiro Y; Soeda T; Nogami K
Haemophilia; 2023 Nov; 29(6):1529-1538. PubMed ID: 37766492
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
Schmitt C; Adamkewicz JI; Xu J; Petry C; Catalani O; Young G; Negrier C; Callaghan MU; Levy GG
Thromb Haemost; 2021 Mar; 121(3):351-360. PubMed ID: 33086400
[TBL] [Abstract][Full Text] [Related]
31. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses.
Kjalke M; Kjelgaard-Hansen M; Andersen S; Hilden I
J Thromb Haemost; 2021 Jul; 19(7):1687-1696. PubMed ID: 33819375
[TBL] [Abstract][Full Text] [Related]
32. "Normal" thrombin generation.
Butenas S; van't Veer C; Mann KG
Blood; 1999 Oct; 94(7):2169-78. PubMed ID: 10498586
[TBL] [Abstract][Full Text] [Related]
33. Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma.
Tripodi A; Chantarangkul V; Novembrino C; Scalambrino E; Boscolo-Anzoletti M; Clerici M; Rossi F; Peyvandi F
Clin Chem Lab Med; 2020 Sep; 59(2):365-371. PubMed ID: 32892172
[TBL] [Abstract][Full Text] [Related]
34. Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation. Synergistic effect in combination with tissue factor pathway inhibitor.
van 't Veer C; Golden NJ; Kalafatis M; Mann KG
J Biol Chem; 1997 Mar; 272(12):7983-94. PubMed ID: 9065469
[TBL] [Abstract][Full Text] [Related]
35. Coagulant potentials of emicizumab in the plasmas from infant and toddler patients with hemophilia A.
Takeyama M; Matsumoto N; Abe H; Harada S; Ogiwara K; Furukawa S; Shimonishi N; Nakajima Y; Yada K; Soeda T; Nogami K
Pediatr Blood Cancer; 2023 Oct; 70(10):e30590. PubMed ID: 37467119
[TBL] [Abstract][Full Text] [Related]
36. Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI-deficient plasma in vitro.
Minami H; Nogami K; Yada K; Ogiwara K; Furukawa S; Soeda T; Kitazawa T; Shima M
J Thromb Haemost; 2019 Jan; 17(1):126-137. PubMed ID: 30444568
[TBL] [Abstract][Full Text] [Related]
37. Thrombomodulin-modified thrombin generation after in vivo recombinant factor VIII treatment in severe hemophilia A.
Dielis AW; Balliël WM; van Oerle R; Hermens WT; Spronk HM; Ten Cate H; Hamulyák K
Haematologica; 2008 Sep; 93(9):1351-7. PubMed ID: 18641016
[TBL] [Abstract][Full Text] [Related]
38. Heterogeneous coagulant potential of emicizumab in neonatal factor VIII-deficient plasma.
Takeyama M; Furukawa S; Onishi T; Noguchi-Sasaki M; Shima M; Nogami K
Pediatr Blood Cancer; 2022 Jul; 69(7):e29731. PubMed ID: 35441786
[TBL] [Abstract][Full Text] [Related]
39. Pharmacodynamics Monitoring of Emicizumab in Patients with Hemophilia A.
Bertaggia Calderara D; Marchi Cappelletti R; Batista Mesquita Sauvage AP; Durual S; Gomez FJ; Zermatten MG; Aliotta A; Casini A; Alberio L
Thromb Haemost; 2023 Oct; 123(10):955-965. PubMed ID: 37336473
[TBL] [Abstract][Full Text] [Related]
40. FVIII/VWF complex displays a greater pro-haemostatic activity than FVIII preparations devoid of VWF: Study in plasma and cell-based models.
Ammollo CT; Semeraro F; Vitulli A; Dirienzo L; Mezzasoma AM; Semeraro N; Gresele P; Colucci M
Haemophilia; 2020 Jul; 26(4):e151-e160. PubMed ID: 32325538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
